SARM / PPARδ Agonist

GW-0742

Next-generation Cardarine. PPARδ agonist with improved selectivity. Endurance and metabolic benefits. ⚠️ Same class as Cardarine — similar theoretical cancer concerns apply.

Build protocol outline Open dose calculator TNHL ebooks

Educational reference only. This page does not diagnose, prescribe, or replace care from a licensed professional. Laws, availability, and clinical appropriateness vary by location.

Reference dose10–20 mg/day

Half-life24 hours

Risk flaghigh

Regulatory noteResearch-only flag

Side effects and watch-outs

⚠️ Same class as Cardarine (GW-501516) — carcinogenicity concern applies to whole PPARδ agonist class
⚠️ No human carcinogenicity data — but mechanism of concern is shared
Limited human safety data
Use with extreme caution